Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLV-324 in Metastatic Solid Tumors
NCT07108114Phase 1Recruiting
- Sponsor
- Solve Therapeutics
- Start
- Aug 2025
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SLV-324 in metastatic solid tumors, sponsored by Solve Therapeutics. Primary endpoint: Maximum Tolerated Dose or Recommended Dosing Regimen at 18 months. Started Aug 2025; status: recruiting.
02
Drugs
SLV-324
03
Conditions
metastatic solid tumors
Beyond the preview
Go deeper on NCT07108114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07108114.